The UK Health Security Agency (UKHSA) issued updated guidance in May 2026 maintaining the use of the 4CMenB vaccine in sexual health programs to prevent gonorrhoea, despite recent clinical trial data failing to show efficacy. While observational studies previously suggested the vaccine might offer cross-protection against Neisseria gonorrhoeae, the Australian GoGoVax trial, presented at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI), found no statistically significant benefit among 600 gay and bisexual participants.
Why did the UKHSA maintain the vaccine guidance?
The UKHSA continues to support the use of the 4CMenB vaccine because public health officials are balancing conflicting data sources. According to the HIV i-Base report, the agency is navigating a divide between observational evidence and randomized controlled trial (RCT) results. While early observational data hinted at a reduction in gonorrhoea incidence among vaccinated populations, the GoGoVax trial represents the third RCT to show no clear protective effect. Health authorities typically prioritize RCT data for clinical guidance, but the persistence of observational signals suggests that the vaccine’s mechanism—or the population settings in which it is used—may require further investigation before a total policy reversal.
The 4CMenB vaccine (Bexsero) was originally developed and licensed specifically to prevent invasive meningococcal disease caused by Neisseria meningitidis, a bacterium closely related to the one that causes gonorrhoea.
How do trial results compare to observational studies?
The scientific community remains divided over the vaccine’s utility due to a stark contrast in research outcomes. Observational studies have historically pointed toward a small but significant reduction in gonorrhoea cases following vaccination. Conversely, the GoGoVax trial results, which were presented by researchers at CROI 2026, failed to replicate these findings in a controlled setting. Simon Collins of HIV i-Base notes that this discrepancy has led to a heated debate, with some experts calling for an end to the program, while others argue that ongoing studies may eventually clarify whether a benefit exists in specific contexts.
What happens next for gonorrhoea prevention research?
Future trends in sexual health policy will likely hinge on the outcomes of ongoing trials that remain in progress. Because the GoGoVax study was the third trial to return negative results, the pressure on researchers to identify why previous observational data appeared positive is increasing. If subsequent studies continue to show no benefit, it is probable that the UKHSA and other international health bodies will re-evaluate the cost-effectiveness and clinical justification for using a meningococcal vaccine as an off-label tool for gonorrhoea control.
When reviewing public health guidance, always distinguish between “observational” data, which tracks real-world outcomes, and “randomized controlled trials,” which are designed to eliminate bias and isolate the vaccine’s specific effect.
Frequently Asked Questions
Is the 4CMenB vaccine effective against gonorrhoea?
Current randomized controlled trial data, including the GoGoVax study, has not demonstrated that the 4CMenB vaccine prevents gonorrhoea. While some observational reports suggested a benefit, these have not been confirmed in clinical trials.
Why is the vaccine still being used in sexual health programs?
According to UKHSA guidance, the program remains active as researchers continue to analyze data from multiple sources. Public health agencies are currently weighing the observational signals against the negative results of recent trials.
What should patients do if they are concerned about gonorrhoea?
Patients should rely on established, evidence-based prevention methods, such as consistent condom use and regular STI screening, as recommended by local sexual health clinics. Consult a healthcare provider for personalized advice.
Have you encountered questions about vaccine-based STI prevention in your practice or community? Join the conversation by leaving a comment below, or subscribe to our newsletter for the latest updates on infectious disease research.
